ISTAART Professional Interest Area (PIA) Events





Join the Professional Interest Areas (PIAs) of the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) on Saturday, July 21 for PIA Day at AAIC. PIA Day hosts a full day of targeted scientific sessions organized by PIA leaders. Members may attend any of the PIA Day sessions or business meetings regardless of PIA membership.

Many of the PIAs will also host their annual business meeting on PIA Day, although some business meetings will take place throughout the week of AAIC. PIA business meetings are an opportunity to receive updates on activities, engage in critical conversations about issues affecting the field, network with peers from across the world and determine objectives for the upcoming year.

Daily Schedule

Educational Workshops (presented by PIAs; open to members and non-members; registration fee required)

Educational Workshop: Basic Neuroimaging in Dementia
Hosted by the Neuroimaging PIA
Marriott Marquis, Grand Horizon B
8 a.m. – 5 p.m.

Educational Workshop: The Basics of Fluid Biomarkers in Alzheimer’s Disease
Hosted by the Biofluid Based Biomarkers PIA
Marriott Marquis, Glessner House
8 a.m. – 5 p.m.

Educational Workshop: Contemporary Issues in Clinical Trials Methods
Hosted by the Clinical Trials Advancement and Methods PIA
Marriott Marquis, Grand Horizon A
8 a.m. – 5 p.m.

Preconferences (presented by PIAs; open to members and non-members; registration fee required)

Neuroimaging PIA
Alzheimer's Imaging Consortium (AIC) Preconference
Hosted by the Neuroimaging PIA
McCormick Place, Room 183

8 a.m. – 5:30 p.m.

Alzheimer’s Imaging Consortium Reception
Marriott Marquis, Great Lake D-G
5:30 – 7 p.m.

Technology PIA
Technology and Dementia Preconference
Hosted by the Technology PIA
Marriott Marquis, Grand Horizon A-C

9 a.m. – 4:30 p.m.

Technology and Dementia PIA Business Meeting*
Marriott Marquis, Grand Horizon A-C
4:45 – 5:45 p.m.
*open to members only; no registration required

PIA Day Events

8:30 – 10 a.m.

Cognition PIA
Hyatt Regency McCormick Place: Dusable
Scientific Session: 8:30 – 10 a.m. | Business Meeting: Wednesday


8:30 – 8:40 a.m. Andreas Monsch, Opening Remarks and Introduction

8:40 – 9:00 a.m. Mario Parra M.D., Ph.D., Short-term Memory Binding as a Marker for Alzheimer’s Disease

9:00 – 9:20 a.m. Marina Boccardi, Ph.D., European Harmonization Initiative in Neuropsychology

9:20 – 9:40 a.m. Emily Edmonds, Ph.D., Neuropsychological Approaches to Identifying MCI and Preclinical AD

9:40 – 10:00 a.m. Kathleen Welsh-Bohmer, Ph.D., Neuropsychological Assessment in the TOMMORROW Clinical Trial

9 – 11:30 a.m.

Design and Data Analytics PIA
Hyatt Regency McCormick Place: Clark
Scientific Session: 9 – 10:30 a.m | Business Meeting: 10:30 – 11:30 a.m.

DaDA Scientific Session: Resources and Approaches for Multi-Study Analysis to Advance Research on Dementia. This session will provide an overview and discussion of multistudy replication research and highlight several resources that support access to key data sets and longitudinal data analytics.


9:00 – 9:10 a.m. Scott Hofer, Opening Remarks, Oregon Health & Science University, Portland, OR, USA

9:10 – 9:20 a.m. Sarah Bauermeister, Dementias Platform UK (DPUK): Data Portal: Bringing Researchers to Data and Using the Power of Cohorts, University of Oxford, Oxford, United Kingdom

9:20 – 9:30 a.m. Ivan Koychev, University of Oxford, Oxford, United Kingdom

9:30 – 9:50 a.m. Jyl Boline, Global Alzheimer's Association Interactive Network (GAAIN): A gateway to dementia data, University of Southern California, Los Angeles, USA

9:50 – 10:10 a.m. Graciela Muniz-Terrera, Integrative Analysis of Longitudinal Studies of Aging and Dementia, University of Edinburgh, Edinburgh, United Kingdom

10:10 – 10:30 a.m. Michael Donohue, Closing Remarks and Discussion: Alternative and complementary approaches for advancing research on dementia, University of Southern California, Los Angeles, USA

Diversity and Disparities PIA
Hyatt Regency McCormick Place: Burnham
Scientific Session: 9 – 10:30 a.m. | Business Meeting: 10:30 – 11:30 a.m.


9:00 – 9:03 a.m. Dr. Yakeel T. Quiroz, PIA Chair, Opening Remarks

New Perspectives and Updates on Clinical Trial Participation Among Diverse Populations
Dr. Yakeel T. Quiroz
Dr. Mario A. Parra

9:03 – 9:18 a.m. Dr. Sid O’Bryant, Perspectives on Ethnic and Racial Disparities in Alzheimer’s Disease and Related Dementias: Update and Areas of Immediate Need

9:18 – 9:33 a.m. Dr. Francisco Lopera, Recruitment in Prevention Clinical Trials: Experience from the Alzheimer’s Prevention Initiative-Colombia

9:33 – 9:45 a.m. Ricardo Allegri, South America's AD Clinical Trial: Challenges and Opportunities

9:45 – 10:00 a.m. Dr. Jonathan D. Jackson, New Recommendations to Support Diverse & Inclusive Recruitment at the Local Level: The National Strategy for Alzheimer's Disease Clinical Research Recruitment & Participation (ADRP)

Rapid-Fire Presentations on Diversity & Disparity Topics
Dr. Ganesh Babulal
Dr. Megan Zuelsdorff

10:00 –10:03 a.m. Mary Austrom, A Community-Based Outreach Model to Increase African American Participation in AD Research

10:03 –10:06 a.m. Bruno Kajiyama, Enhancing Psychoeducation to Cope with Dementia Caregiving, Reduce Depressive Symptoms, and Alleviate Stress with an Online Video Program: A Randomized Clinical Trial

10:06 –10:09 a.m. Jorge Llibre Guerra, African Admixture: Implications for Cognitive Decline in AD

10:09 – 10:11 a.m. Nicolas Cherbuin, Chronic Obstructive Pulmonary Disease (COPD), Dementia Risk, and Mortality: An Epidemiological Investigation in Low to Middle Income Countries

10:11 –10:14 a.m. Priscilla Vasquez, Cognitive Stimulation and Cognitive Function Among Middle-Aged and Older Hispanic/Latino Adults in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL)

10:14 –10:17 a.m. Samantha Burnham, Concorde-AD: An International Network of Cohorts for Better Understanding of Alzheimer’s Disease

10:17 –10:20 a.m. Kylie Radford, Neural Correlates of Early Life Stress in a Population at Higher Risk for Dementia: A Pilot Study in Older Aboriginal Australians

10:20 –10:23 a.m German Falasco, Brain asymmetries in normal and pathological aging: A molecular imaging perspective

10:23 –10:26 a.m. Gonzalo Farias, Tau in platelets as a biomarker for Alzheimer's disease and related neurodegenerative conditions

10:26 –10:30 a.m. Dr. Mario A Parra, PIA Program Chair, Closing Remarks

Electrophysiology PIA
Hyatt Regency McCormick Place: Adler
Scientific Session: 9 – 10:30 a.m. | Business Meeting: 10:30 – 11:30 a.m.

This session will highlight uses of neurophysiological methods such as cellular electrophysiology and electroencephalography for preclinical and clinical applications and drug discovery in Alzheimer’s disease.

The pathophysiological features of Alzheimer’s Disease are broadly consistent (e.g. extracellular deposition of amyloid beta 1-42 and intracellular accumulation of phospho-tau) but the clinical phenotype is heterogeneous with different manifestations of the symptoms over time. Several structural, molecular, and functional neuroimaging markers capture important underlying cortical and subcortical abnormalities. However, they cannot explore a potentially critical angle of the Alzheimer’s disease as a pathology of distributed cognitive systems. They do not have the time resolution for probing the neurophysiological mechanisms of neural synchronization and coupling in the complex linear and nonlinear interactions at millisecond time scale. This Session will highlight new findings obtained from neurophysiological methods studying those interactions in neuronal circuitry and signal transmission at spatial macro-, meso-, and micro-scale, conferred by Alzheimer’s disease-specific pathologies in living systems. Furthermore, the Session will focus on the issue of translation (from preclinical to clinical) vs. back-translation (from clinical to preclinical) of electrophysiology biomarkers in Alzheimer’s research and drug discovery and development. Finally, findings on the cross-modal (e.g. neuroimaging) validity and specificity of the electrophysiological markers of Alzheimer’s disease will be presented and discussed.

The above contents and concepts are the basis of a White Paper in preparation by the members of Electrophysiology PIA for the submission to Alzheimer's and Dementia journal. The White Paper (at this Session) aims at raising the awareness of the ISTAART members on the peculiar added value of electrophysiological markers for the Society mission.

Session Chairs: Fiona Randall (EISAI, Boston, USA) and Claudio Babiloni (Sapienza University Rome, Italy).


9 – 9:20 a.m. Wilhelmus (Pim) Drinkenburg, Neurophysiological Assessment of Neural Network Excitability, Plasticity, and Connectivity in a Preclinical Mouse Model of Alzheimer’s disease pathology, Janssen Research & Development, Beerse, Belgium

9:25 – 9:45 a.m. Mihaly Hajos, Hippocampal and cortical network dynamics in transgenic rodents modeling Alzheimer's disease pathology, Yale School of Medicine and Biogen, USA

9:50 – 10:10 p.m. Heikki Tanila, Characterization of epileptic spiking associated with brain amyloidosis in APP/PS1 mice as new readouts in preclinical treatment trials, University of Eastern Finland, Kuopio, Finland

10:15 – 10:35 p.m. Lucia Farotti, Lucilla Parnetti and Cinzia Costa, Epilepsy, amyloid-β, and D1 dopamine receptors: a possible pathogenetic link between AD and subclinical Epilepsy, University of Perugia, Italy

10:40 – 11:00 p.m. Claudio Babiloni, Cortical excitability as revealed by cortical EEG biomarkers in patients with prodromal Alzheimer's disease and Dementia with Lewy Bodies, Sapienza University of Rome, Italy

11:05 – 11:25 p.m. Stefan Teipel, Brain amyloid deposition and EEG biomarkers in patients with preclinical Alzheimer's disease: advancements of the Insight-PreAD project, University of Paris "Sorbonne", Paris, France

10:30 a.m. Noon

Reserve, Resilience and Protective Factors PIA
Hyatt Regency McCormick Place: Field
Scientific Session: 10:30 a.m. – 12 p.m. | Business Meeting: Wednesday

Research on reserve, resilience, and protective factors in Alzheimer's disease (AD) has received growing attention, driven by the repeated finding that higher levels of life experiences such as cognitive, social and physical activities are associated with both reduced risk and delayed onset of dementia. The Reserve, Resilience and Protective Factors PIA focuses on epidemiologic, clinical/neuropsychological and neuroimaging/biomarker approaches to understanding reserve and resilience. The PIA will also explore intervention strategies that target mechanisms underlying reserve or resilience in order to promote individual brain health and prevent or delay the onset of dementia. Our objectives include: 1) Establish a collaborative forum and network to foster knowledge and research on the mechanisms that may promote reserve and resilience and help prevent or delay cognitive aging and Alzheimer's disease. 2) Develop consensus guidelines on research criteria for studying brain reserve and resilience, and propose strategies to investigate the different underlying brain mechanisms (neuroprotective or compensatory). 3) Promote collaborative projects on the topic, including joint prospective neuroimaging studies, joint grant applications, and merging data sets collected by PIA members. This year’s PIA day will feature 11 data blitz presentations on reserve & resilience from our PIA members.


10:30 – 10:35 a.m. Yaakov Stern, Opening Remarks, Columbia University, United States

10:35 – 10:43 a.m. Anja Soldan, Vascular risks and cognitive reserve are differentially related to longitudinal cognitive trajectories, Cognitive Neuroscience Division, Department of Neurology

10:43 – 10:51 a.m. Chinedu T Udeh- Momoh, Lifetime measures of reserve attenuates Cortisol and β- Amyloid-related risk of Alzheimer's disease Clinical Progression from the Pre- symptomatic Phase, Imperial College London, London, United Kingdom

10:51 – 10:59 a.m. Kylie Radford, Resilience, Cognitive Decline and Dementia in Older Aboriginal Australians: A Longitudinal, Population Based Study, Neuroscience Research Australia, Sydney, Australia

10:59 – 11:07 a.m. Eero Vuoksimaa, Does education have a causal effect on old age cognitive functioning? A population-based quasi-e,xperimental twin study, Institute for Molecular Medicine Finland, University of Helsinki

11:07 – 11:15 a.m. Elisa Resende, White matter microstructure in illiterate versus low literate elderly: preliminary findings, University of California, San Francisco / Trinity College Dublin

11:15 – 11:23 a.m. Katerina Sheardova, The effect of spiritual well-being (transcendental and non- transcendental domain) on regional brain atrophy in non- demented subjects with memory complaints. 3 year follow up data from Czech Brain Aging study, International Clinical Research Center, St.Anne's University Hospital Brno, Brno, Czech Republic

11:23 – 11:31 a.m. Luca Kleineidam, A generic latent variable approach for measuring Cognitive Reserve: Phenotype validation and genetic association results, Department of Neurodegenerative Diseases and Geriatric Psychiatry, University of Bonn, Bonn, Germany

11:31 – 11:39 a.m. Eider M Arenaza- Urquijo, Using Resistance Vs. Resilience to Alzheimer's disease in preclinical studies, Mayo Clinic, Rochester, Minnesota, USA

11:39 – 11:47 a.m. Anita van Loenhoud, Using resting BOLD task potency to derive a task-invariant cognitive reserve network, Department of Neurology and Alzheimer Center, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands

11:47 – 11:55 a.m. Sylvie Belleville, Temporal lobe activation moderates the detrimental effect of hippocampal atrophy on episodic memory and contributes to cognitive reserve: Results from the CIMA-Q cohort, Centre de recherche de l'Institut Universitaire de gériatrie de Montréal

11:55 a.m. – 12:03 p.m. Lídia Vaqué Alcázar, Modulation of 'cognitive reserve working memory networks' with high definition transcranial direct current stimulation (HD-tDCS), Medical Psychology Unit. Department of Medicine, Faculty of Medicine and Health Sciences, University of Barcelona

12:03 – 12:08 p.m. Yaakov Stern, Closing Remarks

Subjective Cognitive Decline PIA
Hyatt Regency McCormick Place: Dusable
Scientific Session: 10:30 a.m. – 12 p.m. | Business Meeting: Monday

This year's scientific meeting of the SCD PIA will have an attractive program with a strongly interactive nature. Presenters will provide results and updates on exciting new studies, covering a range of topics. We expect that there will be ample time for discussion of results and fostering new ideas for collaboration.


Hot Topic

10:30 – 10:35 a.m. Frank Jessen, SCD in the 2018 NIA-AA research framework, University of Cologne, Germany

Topic 1: SCD in the prediction and monitoring of longitudinal cognitive decline

10:35 – 10:45 a.m. Inge Verberk, Plasma amyloid is related to rate of cognitive decline in SCD: the SCIENCe project

Topic 2: Clinical approaches to SCD

10:45 – 10:55 a.m. Amy Jenkins, Gold standard care pathway for SCD in Swansea, South Wales

10:45 – 10:55 a.m. Athene Lee, The effects of subjective cognitive decline on APOE genotype disclosure in the Butler Alzheimer's Prevention Registry

Topic 3: The relationship of depression and anxiety with SCD in the context of AD

11:05 – 11:15 a.m. Sietske Sikkes, Jenn Gatchel, Item-level Analysis of SCD and Depression assessments in relationship to amyloid burden

11:15 – 11:25 a.m. Alexander J. Ehrenberg, Association of neuropsychiatric symptoms with post-mortem AD pathology

11:25 – 11:35 a.m. Angeliki Tsapanou, Sleep and Subjective cognitive complaints (SCC)- data from the WHICAP and the HELIAD study

11:35 a.m. – 12 p.m. Discussion of presentation and ongoing and new collaborative projects

12 – 2:30 p.m.

Neuropsychiatric Syndromes PIA
Hyatt Regency McCormick Place: Adler
Scientific Session: 12 – 1:30 p.m. | Business Meeting: 1:30 – 2:30 p.m.

Neuropsychiatric Syndromes (NPS) in Neurodegenerative Disease are widely acknowledged as a major public-health priority area in the field of neurodegenerative disease. Experts recognize the universal prevalence of these symptoms in Alzheimer's and related conditions, the significant added disability for patients and caregivers associated with NPS and the relative scarcity of effective treatments for NPS. The NPS PIA focuses on defining clinical entities that will serve as targets for research and treatment development in later years. Sub-groups related to specific NPS in Alzheimer's disease, for example apathy, agitation and psychosis, as well as a group working on mild behavioral impairment (MBI) work to develop a series of next steps to meet the PIA's overall objective. The NPS PIA Day session will feature various presentations, followed by a minute madness session highlighting NPS-related posters.


12 – 12:05 p.m. Krista Lanctôt, Opening Remarks, Sunnybrook Research Institute, Toronto, Canada

12:05 – 12:15 p.m. Richard Ryan Darby, New Investigator awardee presentation, Vanderbilt University Medical Center, Nashville,TN, USA

12:15 – 12:25 p.m. Janne Papma, New Investigator awardee presentation, VU University Medical

12:25 – 12:35 p.m. Zahinoor Ismail, MBI Update, University of Calgary, Calgary, Canada

12:35 – 1:20 p.m. Minute Madness Presenters

1:20 – 1:30 p.m. Joanne Bell, Closing remarks, Syneos Health, Wilmington, NC, USA

Nutrition, Metabolism and Dementia PIA
Hyatt Regency McCormick Place: Clark
Scientific Session: 12 – 1:30 p.m. | Business Meeting: 1:30 – 2:30 p.m.

The field of study of nutrition and metabolism in relation to cognition and dementia is particularly complex and inconsistencies in the literature make the development of sound public health recommendations a major challenge. This interest group is trying to create a 'hub' at the Association to unite scientists and clinicians who are interested in advancing the field.

During our PIA day scientific session we aspire to provide the opportunity to present to as many researchers in this field. Our schedule will take the form of a data blitz with scientific work of both basic scientific and clinical orientation being included. Each presentation will last 5 minutes, followed by 1 minute of brief discussion. Our 90-minute scientific session will be followed by our annual business meeting, which includes among others updates on white paper efforts currently in progress and other collaborative efforts and plans. Our business meeting also provides excellent networking opportunities.


12 – 12:02 p.m. Nikos Scarmeas, Opening Remarks, Columbia University and the National and Kapodistrian University of Athens, Greece

12:05 – 12:10 a.m. Shyamala Mruthinti, Mechanisms of Curcumin-induced Protection To Prevent Neuronal Integrity and Synaptic Loss of Differentiated PC- 12 Cells from Cytotoxicity Produced after Exposure to CML and Aβ42 , Datta ImmunoChem.Inc

12:10 – 12:15 a.m. Kevin N. Hascup, Obesity-Induced Insulin Resistance Causes Hippocampal Glutamatergic Dysregulation and Impairs Cognition in AβPP/PS1 Mice, Southern Illinois University School of Medicine

12:15 – 12:20 p.m. Alexandra Plagman, Cholecystokinin Increases Gray Matter and Glucose Uptake in the Brain Leading to Increased Cognitive Function, but Is Correlated with an Accumulation of Tau and Ptau Formations, Iowa State University

12:20 – 12:25 p.m. Cory Funk, Modeling metabolism in Alzheimer's Disease, Institute for Systems Biology

12:25 – 12:30 p.m. Auriel A. Willette, Longitudinal Association of Insulin Resistance and Alzheimer's Disease Outcomes Across the Alzheimer's Disease Spectrum, Iowa State University, United States

12:30 – 12:35 p.m. Kelsey McLimans , Serum vitamin B12 and 5-methyltetrahydrofolate- homocysteine methyltransferase reductase, Iowa State University, United States

12:35 – 12:40 p.m. Kelsey McLimans, Diacyl Phosphatidylcholines Associated with Decreased Gray Matter in the Default Mode Network, Worse Cognition, and Increased Aβ1-42 Tissue Deposition across the AD Spectrum, Iowa State University, United States

12:40 – 12:45 p.m. Thomas Holland, Nutritional Intake of Flavonols May Decrease the Rate of Alzheimer's Disease in an Elderly Population, Rush University Medical Center

12:45 – 12:50 p.m. Andrea McGrattan, Acceptability of a tailored Mediterranean Lifestyle Education Resource among patients with Mild Cognitive Impairment: A Qualitative Study, Centre for Public Health, Queen's University Belfast

12:50 – 12:55 p.m. Francisca de Leeuw, Nutritional markers associated with clinical progression in patients with mild cognitive impairment and subjective cognitive decline: the NUDAD project, Alzheimer’s Center, VU medical center, Amsterdam, The Netherlands

12:55 – 1 p.m. Cécilia Samieri, Using network science tools to identify novel diet patterns in prodromal dementia: The Three-City Study, INSERM U1219 and University of Bordeaux

1 – 1:05 p.m. Puja Agarwal, Brain Bromine Levels Associated with Alzheimer's disease Neuropathology and Cerebral Infarcts, Rush University Medical Center

1:05 – 1:07 p.m. Nikolaos Scarmeas, Closing Remarks, Columbia University/University of Athens

Vascular Cognitive Disorders PIA
Hyatt Regency McCormick Place: Burnham
Scientific Session: 12 – 1:30 p.m. | Business Meeting: 1:30 – 2:30 p.m.

In the Alzheimer field we have seen an increase in the number of large randomized clinical trials because there is a specific disease process (accumulation of amyloid) that can be assessed with biomarkers and targeted with drugs. This ability to measure a putative pathology with a biomarker allows to demonstrate presence of the target as well as target engagement in trial participants. For vascular cognitive disorders (VCD) risk factors are known, we can measure downstream vascular brain damage on MRI, and assess cognitive consequences. Yet, much less is known about the core disease processes at the level of the blood vessels and there are no established disease modifying treatments. To move the field ahead we need to identify the treatment targets that are at the base of the VCD. We need biomarkers to measure these targets and specific drugs to engage them. The symposium will cover the latest insights in the core processes underlying VCD, in biomarker development to probe these processes, and in drug therapy for VCD.


Chair: Adam Brickman, Columbia University, NY

12:00 – 12:10 p.m. Adam Brickman, Opening and introduction on Symposium Background

12:10 – 12:25 p.m. Donna Wilcock, Vascular cognitive disorders: What are treatable targets?, University of Kentucky, Lexington

12:25 – 12:40 p.m. Hanzhang Lu, Vascular cognitive disorders: Which biomarkers can show target engagement in treatment trials?, The Russell H. Morgan Department of Radiology & Radiological Science, Johns Hopkins University School of Medicine

12:40 – 12:55 p.m. Niels Prins, Vascular cognitive disorders: Lessons from earlier trials, Brain Research Center Amsterdam

12:55 – 1:05 p.m. Questions/panel discussion

1:05 – 1:55 p.m. Round Table Discussion: Which treatable target should be the focus of the next RCT in VCD / how to get to that trial

1:15 – 1:25 p.m. Brief (i.e max 90 seconds) pitches on output round table discussion

1:25 – 1:30 p.m. Adam Brickman, Closing Remarks

12:30 – 3 p.m.

Down Syndrome and Alzheimer's Disease PIA
Hyatt Regency McCormick Place: Field
Business Meeting: 12:30 – 1:30 p.m. | Scientific Session: 1:30 – 3 p.m.

Individuals with Down syndrome, characterized by a triplication of chromosome 21, consistently develop Alzheimer's pathology in middle age, yet there is delay in dementia onset, and a high variability in this delay. The Down Syndrome and Alzheimer's Disease PIA will highlight new, translational research from leaders in the Down syndrome field. We will follow the formal presentations from established investigators with a "data blitz," consisting of short presentations from trainees in the Down syndrome field.


1:30 – 1:51 p.m. Jorge Busciglio, Ph.D., TBD, University of California, Irvine, Irvine CA, USA

1:52 – 2:13 p.m. Matthew Janicki Ph.D., Some Observations on Social Care Using Dementia Capable Group Homes, , University of Illinois, Chicago, Chicago, IL USA

2:14 – 2:35 p.m. Maria Carmona-Iragui, M.D., Ph.D, Plasma Biomarkers Diagnostic Performance to Diagnose Alzheimer´s disease in Down syndrome. Memory Unit, Alzheimer-Down Unit, Barcelona, Spain

2:36 – 2:46 p.m. Data Blitz Session
Katherine Koenig, Imaging in Young DS Adults, Cleveland Clinic, Cleveland, OH USA
Karly Cody, Amyloid Burden and Cortical Atrophy in Non-demented Down Syndrome, University of Wisconsin, Madison WI USA

2:46 – 3:00 p.m. Laurie Ryan, Ph.D., DS Funding Update from NIA, NIA / NIH, Bethesda, MD USA

Non-pharmacological Interventions PIA
Hyatt Regency McCormick Place: Dusable
Business Meeting: 12:30 – 1:30 p.m. | Scientific Session: 1:30 – 3 p.m.

A biopsychosocial framework of dementia emphasizes that overall functioning cannot be solely explained by underlying brain pathology, and there is evidence that certain barriers to activity and participation can be removed through effective non-pharmacological interventions, and that the experience of the person with dementia and their families can be improved through appropriate management of personal, social and environmental factors. In addition, psychosocial, lifestyle and environmental factors may impact on risk of developing dementia, and interventions in these areas can contribute to risk reduction.

The Scientific Meeting of the Non-Pharmacological Interventions PIA, which will be held on Saturday July 21th as part of PIA Day, will be an opportunity to learn about the latest progress in non-pharmacological interventions, including but not limited to, cognition and function-oriented treatments, physical activity and dietary interventions targeting older adults with dementia or at risk of dementia. We are delighted to announce that two leading researchers, Henry Brodaty (Ph.D.), and Sylvie Belleville (Ph.D.), have accepted our invitation to give keynote presentations during this session and to present their exciting research. The program will also include a Data Blitz session, in which six additional PIA members will present brief 5-minute updates on their research.


1:30 – 1:40 p.m. Executive Committee, Introduction And Opening Remarks

1:40 – 1:55 p.m. Henry Brodaty, (Introduction: Alex Bahar-Fuchs), Keynote Speaker, Scientia Professor, Challenges and opportunities in NPI research in dementia, Centre for Healthy Brain Ageing, the University of New South Wales, Australia

1:55 – 2:25 p.m. Data Blitz Presentations (Introduction: Yi Tang)

1:55 – 2:00 p.m. Linda Chao, Effects of Transcranial and Intranasal Photobiomodulation for Cognitive and Behavioral Function, Cerebral Perfusion and Resting State Functional Connectivity in Patients with Dementia – A Pilot Clinical Trial, UCSF and San Francisco VAMC

2:00 – 2:05 p.m. Hope Schwartz, The Brain Health Champion Study: Promoting Non-Pharmacological Interventions in Cognitive Disorders, Brigham and Women's Hospital / Harvard Medical School

2:05 – 2:10 p.m. Yi Tang, The efficacy of computerized Cognitive training in patients with VAsCular Cognitive Impairment, No dEmentia (the Cog-VACCINE study), Xuan Wu Hospital, Capital Medical University, China

2:10 – 2:15 p.m. Hiroko Dodge, Internet-based social interactions as a tool to enhance cognitive reserve, Oregon Health & Science University / University of Michigan

2:15 – 2:20 p.m. Geeske Peeters, Behaviour change techniques in computerized cognitive training for cognitively healthy older adults: a systematic review, Global Brain Health Institute, University of California San Francisco / Trinity College Dublin

2:20 – 2:25 p.m. Annalena Venneri, The effect of cognitive training is modulated by education levels and by the load of white-matter hyperintensities, University of Sheffield

2:25 – 2:40 p.m. Sylvie Belleville, (Introduction: Alex Bahar-Fuchs, Keynote Speaker, Director, The contribution of virtual reality to cognitive interventions: moving from physical to virtual and back, Research Center Institut Universitaire de Gériatrie de Montréal, University of Montréal

2:40 – 3:00 p.m. Executive Committee, Closing Remarks

3 – 5:30 p.m.

Biofluid Based Biomarkers PIA
Hyatt Regency McCormick Place: Adler
Scientific Session: 3 – 4:30 p.m. | Business Meeting: 4:30– 5:30 p.m.

The objective of this PIA is to provide an effective means of communication across research and industry leaders for the development and advancement of the clinical and research applications of biofluid biomarkers in Alzheimer's and other neurodegenerative diseases.


3 – 3:05 p.m. Michelle Mielke, Opening Remarks, Mayo Clinic, MN, USA

3:05 – 3:10 p.m. Sid O'Bryant, Saliva Biomarker Working Group Update, UNT Health Science Center, TX, USA

3:10 – 3:15p.m. Jeffrey Dage, Context of Use Working Group Update, Eli Lilly, IN, USA

3:15 – 3:20 p.m. Danni Li, Reference Ranges Working Group Update, University of Minnesota, MN, USA

3:20 – 3:32 p.m. Andrew Merluzzi, Neurofilament Light Protein is Associated with Cognitive Decline Within the ATN Model, University of Wisconsin, WI, USA

3:32 – 3:44 p.m. Ashvini Keshavan, Certain Plasma N-Terminal Tau Fragments Are Elevated in AD and AD-MCI Compared to Controls, Institute of Neurology, University College London, London, United Kingdom

3:44 – 3:56 p.m. Rosha Babapour Mofrad, Sex differences in cerebrospinal fluid biomarker concentrations across clinical stages, Neurochemistry Laboratory, Department of Clinical Chemistry, VU University Medical Center, Netherlands

3:56 – 4:08 p.m. Amy Nguyen, Routine Clinical Use of Mass Spectrometry for Quantification of Amyloid-ß 1-40 and 1-42: Pre-Analytical and Analytical Considerations, University of British Columbia, Canada

4:08 – 4:20 p.m. Gregory Day, Quantifying CSF Biofluid Biomarkers of Neuronal Injury, Neuroinflammation and Neurotransmission in Antibody-Mediated Encephalitis, Washington University School of Medicine, MS, USA

4:20 – 4:30 p.m. Michelle Mielke,Closing Remarks, Mayo Clinic, United States

Immunity and Neurodegeneration PIA
Hyatt Regency McCormick Place: Burnham
Scientific Session: 3 – 4:30 p.m. | Business Meeting: 4:30– 5:30 p.m.

Confused about whether microglial activation in Alzheimer's disease is helpful or damaging? Join the Immunity and Neurodegeneration PIA to debate the resolution: The focus of innate immune therapies to treat Alzheimer's disease should be to suppress innate immune reactions. The debate will be followed by a rapid fire, data blitz session presented by young investigators focusing on Immunity and Neurodegeneration. The Immunity and Neurodegeneration PIA is a working group of basic, translational and clinical researchers interested in mechanisms controlling neurodegeneration mediated by innate and adaptive immunity. Goals of the PIA include stimulating interdisciplinary research, identifying knowledge gaps on issues critical to the field, and promoting consensus, collegiality and career advancement among investigators in the field. Please join us for sensational scientific program, followed by a business meeting highlighting future goals and networking opportunities.


3:00 – 3:05 p.m. Marcia Gordon, Overview of the program, Michigan State University, Grand Rapids, MI, USA

3:05 – 3:10 p.m. Karl Herrup, Debate Moderator, Introduction, University of Science and Technology, Hong Kong

3:10 – 3:50 p.m. Debate:
David Morgan, Affirmative, Michigan State University, Grand Rapids, MI, USA
Gary Landreth, Opposition, Indiana University, Indianapolis, IN, USA

3:50 – 3:55 p.m. Doris Chen, Transcriptome analysis reveals impairment in glycolysis, mitochondrial bioenergy, and synaptic transmission in a transgenic mouse model of Alzheimer's disease with neuronal expression of Aβ, University of Kansas, Lawrence, KS, USA

3:57 – 4:02 p.m. Phillip DiGiacomo, X-Ray Fluorescence Imaging and Absorption Spectroscopy to Evaluate Iron Distribution and Oxidative State in the AD Hippocampus, Stanford University, Palo Alto, CA, USA

4:04 – 4:09 p.m. Yuan Dong, Altered Homeostasis of Peripheral Neutrophils Correlates with Alzheimer's Disease Progression, INSERM, Paris, France

4:11 – 4:16 p.m. Nicholas Fitz
ApoE Isoform Specific Effects on Amyloid-β-induced Changes in Microglial Response, University of Pittsburgh, Pittsburgh, PA, USA

4:18 – 4:23 p.m. Sitara Sankar, Heme and hemoglobin suppress amyloid beta-mediated astrocyte immune function, Georgia Institute of Technology, Atlanta, GA, USA

4:25 – 4:30 p.m. Md Golam Sharoar, The Constitution of Dystrophic Neurites in Aging and in Alzheimer's Disease Mouse Model Brain and Their 3D Structures, University of Connecticut Health, Farmington, CT, USA

4:32 – 4:38 p.m. Levi Wood, Cerebral Blood Flow Inversely Correlates with Amyloid Pathology and Neuroinflammation after Mild Traumatic Brain Injury, Georgia Institute of Technology

Perioperative Cognition and Delirium PIA
Hyatt Regency McCormick Place: Clark
Scientific Session: 3 – 4:30 p.m. | Business Meeting: 4:30– 5:30 p.m.

The Perioperative Cognition and Delirium PIA is a group of investigators who are concerned about cognitive outcomes in our older population of patients who undergo anesthesia and surgery. Our multidisciplinary approach to the study of postoperative cognitive disorders has the long-range goal of modulating what we do in the perioperative period to improve postoperative cognitive outcomes including delirium, and help our patients make informed choices. Our most recent collaborative work includes the International Nomenclature Consensus Work Group, which has led an effort to revise the nomenclature for what had been loosely termed, "Postoperative Cognitive Dysfunction" or POCD. We have active collaborations with other investigators from the Alzheimer’s disease research field, and welcome anyone who is interested in this exciting field of investigation.


3:00 – 3:05 p.m. Esther Oh, Introduction, Johns Hopkins University, United States

3:05 – 3:13 p.m. Rod Eckenhoff, Report from AARP/ASA Brain Health Summit, University of Pennsylvania, University of Pennsylvania

3:13 – 3:25 p.m. David Scott, Chronic post-surgical pain, delirium and depression following cardiac surgery, University of Melbourne, Australia

3:25 – 3:37 p.m. Sarinnapha (Fah) Vasunilashorn, Development of a dynamic multi-protein signature of postoperative delirium, Harvard University

3:37 – 3:49 p.m. Niccolo Terrando, Clarifying postoperative neuroinflammation and delirium in a mouse model, Duke University

3:49 – 4:01 p.m. Emma Cunningham, Cerebrospinal fluid/plasma albumin ratio predicts postoperative delirium in an older elective surgical population, Queen’s University Belfast

4:01 – 4:13 p.m. Mariana G. Figueiro, Novel ideas on how to use light to improve post-operative circadian disruption, Rensselaer Polytechnic Institute

4:13 – 4:25 p.m. Lis Evered, NFL and tau predict delirium and neurocognitive disorder postoperative at 3 months, University of Melbourne, Australia

4:25 – 4:30 p.m. Esther Oh, Conclusion & New Investigator Award Ceremony

3:30 – 6 p.m.

Clinical Trials Advancement and Methods PIA
Hyatt Regency McCormick Place: Dusable
Business Meeting: 3:30 – 4:30 p.m. | Scientific Session: 4:30– 6 p.m.

4:30 – 6 p.m.

Atypical Alzheimer's Disease and Associated Syndromes PIA
Hyatt Regency McCormick Place: Field
Scientific Session: 4:30 – 6 p.m. | Business Meeting: Tuesday

The Atypical Alzheimer's Disease and Associated Syndromes PIA is an international community of investigators interested in studying unconventional aspects of Alzheimer’s disease (AD). We provide a forum to discuss what defines atypical and typical AD in order to reveal common misconceptions that may impact patient care, influence animal models, and interfere with biomarker interpretation. Our multi-disciplinary membership is made up of both clinicians and scientists to facilitate a well-rounded approach to investigating atypical AD clinical phenotypes (e.g. posterior cortical atrophy), young onset AD, neuroimaging patterns (e.g. structural MRI, tau PET), and underlying neuropathologic phenotypes (e.g. hippocampal sparing AD). We welcome you to join us this year at our Scientific Session on Saturday, July 21, 2018 from 4:30 – 6:00 p.m. Field Room at the Hyatt Regency McCormick Place.


4:30 – 4:40 p.m. Melissa E. Murray, Opening Remarks, Mayo Clinic, Jacksonville, FL, USA

4:40 – 4:53 p.m. Beau Ances MD, Ph.D., MSc, Rapidly Progressive Dementia: Alzheimer's Disease and Creutzfeldt-Jakob Disease in the Atypical Diagnosis Work-up, Washington University St. Louis, St. Louis, MO, USA

4:53 – 5:06 p.m. Roberta Diehl Rodriguez M.D., Ph.D., Atypical Early-Onset Dementia: The Possible Impact of Multiple Pathologies, University of Sao Paulo, Sao Paulo, Brazil

5:06 – 5:19 p.m. Emily H. Trittschuh, Ph.D., Cognitively-Defined LOAD Subgroups Are Characterized By Heterogeneous Patterns of Relative Deficits in the Five Years Preceding LOAD Diagnosis, University of Washington, Seattle, USA

5:19 – 5:32 p.m. Jurre den Haan, M.D., Assessing changes in the anterior and posterior visual pathway in posterior cortical atrophy and typical Alzheimer's disease, VU University Medical Center, Amsterdam, Netherlands

5:32 – 5:45 p.m. Daniel Ohm, Neuroscience Ph.D. Candidate, Neurofibrillary Tangles are Associated with In Vivo Cortical Atrophy in Primary Progressive Aphasia with Alzheimer’s Disease, Northwestern University, Chicago, IL, USA

5:45 – 5:58 p.m. Fadi S. Hanna Al-Shaikh, Neuroscience Post-baccalaureate, Selective Vulnerability of the Cholinergic System in Neuropathologically-Defined Atypical Alzheimer’s Disease Subtypes, Mayo Clinic Florida, Jacksonville, FL, USA

PIA Business Meeting

Subjective Cognitive Decline PIA
Marriott Marquis, Marina City
Business Meeting: 7 – 8 a.m.

Alliance of Women Alzheimer's Researchers (AWARE) PIA
Hyatt McCormick, Prairie Room
4th Annual AAC® Early Career Mentoring Breakfast: 7:00 – 8:15 a.m.

PIA Business Meetings

Neuroimaging PIA
Marriott Marquis, Marina City
Business Meeting: 12 – 1 p.m.

Alliance of Women Alzheimer's Researchers (AWARE) PIA
Hyatt McCormick, Grant Park Room
Professional Development Panel: "Advancing Women Scientists: An Honest Forum with Global Perspectives about Overcoming Challenging Barriers to Success": 5:30 – 7:30 p.m

Atypical Alzheimer’s Disease and Associated Syndromes PIA
Marriott Marquis, Marina City
Business Meeting: 6 – 7 p.m.

PIA Business Meetings

Cognition PIA
Marriott Marquis, Marina City
Business Meeting: 7 – 8 a.m.

Alliance of Women Alzheimer’s Researchers (AWARE) PIA
Marriott Marquis, Shedd
Business Meeting: 7 – 8 a.m.

Reserve, Resilience and Protective Factors PIA
Marriott Marquis, Marina City
Business Meeting: 6 – 7 p.m.

Join the Conversation #AAIC19






> 1200px
> 992px
> 768px
< 767px